Journal of Community Pharmacy Practice
Vol: 03, No. 02, July-Dec 2023
ISSN: 2799-1199, DOI: 10.55529/jcpp.34.36.46

Research Paper

Guardians of safety: the crucial role of pharmacists in reducing adverse drug reactions

Fahad Nabi[1], Mohd Altaf Dar[2*], Abrar Bashir Malik[3]
[1,2*,3]Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.

Article Info

Article History:
Received: 02 April 2023
Revised: 10 June 2023
Accepted: 18 June 2023
Published: 04 August 2023

Keywords:
Pharmacists
Adverse Drug Reactions
Medication Therapy Management
Pharmacovigilance
Drug Safety

ABSTRACT

Introduction: Today, adverse drug reactions (ADRs) are considered to be one of the concerns in modern healthcare. They are an important cause of morbidity and mortality and costs to the health care system. Their role in the pharmacist is to mitigate these risks by virtue of their knowledge of how to manage medicines, educate patients and conduct pharmacovigilance.
Objective: The objective was to determine how pharmacists could help to minimize ADRs including patient education and comprehensive medication therapy management (MTM), and engaging in pharmacovigilance.
Methods: [Narrative review. The databases searched, the time period covered, and the keywords and inclusion criteria will be stated here. Excessive workload and difficulties reporting ADR were found to be barriers to pharmacist-led ADR reduction. Technological advances and further professional development and interdisciplinary team working were suggested as solutions.
Conclusion: Pharmacists play a crucial role in protecting patient health and improving medication safety. Their contribution to the reduction of ADR can be reinforced by technological advances, by continued professional development and by the interdisciplinary collaboration.

Corresponding Author:
Mohd Altaf Dar
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.
Email: daraltaf490@gmail.com

Copyright © 2023 The Author(s). This is an open access article distributed under the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

An adverse drug response, also known as an ADR, is a potentially hazardous or unanticipated outcome that occurs as a consequence of the administration of therapeutic amounts of medication. Due to

Journal of Community Pharmacy Practice (JCPP)

the impact they have on patient health, the increased utilisation of healthcare services, and the accompanying economic expenses, they constitute a significant public health risk. It is essential to have appropriate treatment in order to improve patient outcomes and reduce healthcare costs. Adverse drug reactions can range from slight discomfort to serious illnesses that threaten a patient's life. Polypharmacy among senior patients, the introduction of novel and complicated medications, and the heterogeneity in individual patient responses are some of the reasons that have contributed to the increasing complexity of pharmacotherapy, which has led to an increase in the risk of adverse drug reactions (ADRs) [1], [2], [3]. Pharmacists are in a strategic position to play a crucial role in the prevention, identification, and management of adverse drug reactions (ADRs) in the current healthcare system for which they are responsible. They are at the forefront of assuring the safety of medications due to their knowledge in pharmacology, medication management, and direct engagement with patients. A thorough medication therapy management (MTM) program, patient education, and active engagement in pharmacovigilance are all included in the responsibilities of chemists, which go beyond simply distributing prescriptions. Each of these responsibilities is essential to lowering the incidence of adverse drug reactions and improving the effectiveness of treatment. The purpose of this paper is to give a comprehensive analysis of the numerous contributions that chemists make to the management of adverse drug reactions (ADRs), as well as the obstacles that they encounter and the potential remedies that could be implemented [4].

2. RELATED WORK

When it comes to reducing adverse drug reactions (ADRs), chemists play a significant role in patient education, which is essential. Education that is effective entails giving patients with information that is both clear and understandable on their medications. This information should include the medications' intended use, any potential adverse effects, and the essential measures to take in the event that adverse effects occur. In order to ensure that patients are aware of how to properly utilise their drugs and recognise the early warning signals of adverse drug reactions (ADRs), chemists employ a variety of training tactics. Education provided by chemists has been shown to considerably enhance patient medication adherence and lower the number of adverse drug reactions (ADRs), according to research investigations [5], [6], [7], [8]. As an illustration, a study conducted discovered that patients who got comprehensive counselling from chemists regarding their medications reported a lower incidence of adverse drug reactions (ADRs) and higher levels of medication adherence in comparison to those who did not receive such counselling. When it comes to improving patient comprehension, chemists frequently employ a variety of education methods, including spoken instructions, written materials, and interactive tools. To ensure that patients have a complete understanding of their treatment regimens and the potential adverse consequences of those regimens, personalised education that is tailored to the specific needs and literacy levels of each individual patient is particularly helpful.

The education of patients about drug interactions, which is a common source of adverse drug reactions (ADRs), is another function that chemists play. Pharmacists play an important role in preventing harmful effects that may be caused by unexpected drug interactions by providing patients with information regarding the possibility of these interactions occurring with other medications, foods, or beverages. Additionally, chemists are able to provide patients with advice on how to manage minor adverse drug reactions (ADRs) and when it is appropriate to seek further medical attention [9], [10]. This empowers patients to take an active role in the management of their medications. Pharmacists offer a complete service known as Medication Therapy Management (MTM) in order to maximise the usage of medications and reduce the risk of adverse drug reactions (ADRs). A comprehensive assessment of all medications that a patient is currently taking is considered part of the MTM process. This review includes prescription drugs, over-the-counter medications, and dietary supplements. It is the purpose of medication therapy management (MTM) to detect and handle medication-related issues that may result in unfavourable effects or therapeutic outcomes that are less than ideal. Different components of a patient's medication regimen are evaluated by chemists who are conducting medication therapy management (MTM). These aspects include drug interactions, dosage errors, therapeutic duplications, and inappropriate medication use.

Research demonstrates that MTM is successful in lowering the incidence of adverse drug reactions (ADRs) and improving the results for patients. Medication therapy management (MTM) services managed by chemists, for instance, have been demonstrated to result in fewer hospitalisations owing to adverse drug reactions (ADRs) and improved medication adherence [10], [11], [12]. The medication review process is an essential part of medication therapy management (MTM). During this process, chemists assess each medication to determine whether or not it is suitable, effective, and safe. During this process, it is necessary to check for the possibility of drug interactions, confirm that the correct dosage is being administered, and determine whether or not to continue treatment. The proactive role that chemists play in the management of pharmaceutical therapy is demonstrated by their ability to recognise and address possible problems before they result in unpleasant responses [13]. Additionally, medication therapy management (MTM) services comprise working together with other medical professionals to ensure that the patient's drug regimens are optimised and in line with the patient's overall treatment blueprint. This coordinated strategy improves the efficacy of pharmacological therapy while simultaneously lowering the likelihood of adverse drug reactions (ADRs).

It is possible for chemists to communicate with physicians, nurses, and other healthcare professionals in order to discuss issues regarding medicine and to make any required revisions to the patient's treatment plan. The study of pharmacovigilance encompasses both the scientific study and the behaviours that are associated with the identification, evaluation, comprehension, and prevention of adverse drug reactions (ADRs). When it comes to pharmacovigilance practices, chemists play a crucial role because they are frequently the first to recognise and report adverse drug reactions (ADRs) that patients encounter [14], [15]. The participation of these individuals in pharmacovigilance contributes to the management of medication safety and the enhancement of drug safety profiles. One of the obligations that chemists have in the field of pharmacovigilance is to document adverse drug reactions (ADRs) and report them to regulatory authorities. These authorities may include the Food and Drug Administration (FDA) or other national and international organisations. The early identification of safety hazards and the development of initiatives to mitigate risks are both possible outcomes that are made possible by this reporting. There is evidence to suggest that pharmacies that have sophisticated pharmacovigilance systems report greater incidence of adverse drug reactions (ADRs), which ultimately results in more thorough drug safety profiles and proactive regulatory measures. Pharmacists are responsible for educating patients on the importance of recognising and reporting adverse reactions, in addition to reporting adverse drug reactions (ADRs). Pharmacists contribute to the collection of vital data for pharmacovigilance systems by urging patients to report any bad effects they experience with their medications on their own. Taking this preventative strategy helps to ensure that drugs are both safe and effective in their intended purpose [16], [17]. In addition, pharmacovigilance methods include maintaining awareness of the most recent safety information and updates concerning any pharmaceuticals that may be administered. It is essential for chemists to be aware of any new safety alerts, recalls, or changes to drug labelling in order to give patients with accurate information and to make decisions on pharmaceutical therapy that are based on factual information. Despite the fact that they play a crucial part in the treatment of adverse drug reactions (ADRs), chemists encounter a number of obstacles and hurdles that can hinder their efficiency. Their capacity to do comprehensive medication evaluations and provide detailed patient education may be hindered by the high workloads and time limits they have, which is one of the most significant challenges they face. There is a possibility that pharmacists in busy community pharmacy settings will have difficulty allocating sufficient time for each patient. This may have the potential to impact the quality of their contacts with patients as well as the efficiency of their instructional efforts [18].

Another important obstacle is the underreporting of adverse drug reactions (ADRs). Some of the factors that contribute to this problem include complicated reporting procedures and a lack of information regarding reporting standards. It is possible that chemist will have trouble navigating adverse drug reaction (ADR) reporting systems, or that they may not completely comprehend the significance of reporting all adverse events. In order to overcome these obstacles, it is necessary to streamline the reporting procedures, raise awareness about the significance of pharmacovigilance, and provide additional training for chemists. In order to overcome these difficulties, technological innovations have the potential

to play a pivotal role. Through the utilisation of clinical decision support systems, electronic health records, and several other technology tools, it is possible to streamline the processes involved in drug management and improve efficiency [19], [20]. Pharmacists can obtain assistance from these technologies in recognising probable adverse drug reactions (ADRs), monitoring prescription therapy, and reporting adverse reactions in a more efficient manner. For chemists to be able to improve their competencies in the management of adverse drug reactions (ADRs), ongoing education and professional development are also crucial. By participating in training programs that concentrate on the most recent developments in pharmacovigilance, patient education strategies, and pharmaceutical therapy management, chemists can increase their ability to handle adverse drug reactions (ADRs) and stay up to date with the best practices in the field [21], [22].

3. METHODOLOGY

To conduct this review, a comprehensive search was performed across several academic databases, including Scopus, Google Scholar, and PubMed. Keywords such as "pharmacists," "adverse drug reactions," "medication therapy management," and "pharmacovigilance" were used to locate relevant papers and articles. The primary focus of the selection criteria was research investigating the role of pharmacists in the management of adverse drug reactions (ADRs), with a particular emphasis on patient education, medication therapy management (MTM), and pharmacovigilance techniques. The review analyzed information obtained from these sources to provide a thorough understanding of how pharmacists contribute to the management of ADRs and to identify solutions for overcoming obstacles. Recent developments in technology and best practices were also considered to offer a contemporary perspective on enhancing pharmacists' involvement in medication safety. Pharmacists play a crucial role in managing ADRs, which are a significant concern in healthcare due to their impact on patient safety and healthcare costs. Pharmacists are well-positioned to identify, monitor, and mitigate ADRs through their expertise in medications and patient care. They can offer personalized medication counseling, conduct thorough medication reviews, and implement MTM programs to optimize drug therapy and minimize the risk of ADRs. The review highlighted several ways in which pharmacists contribute to the management of ADRs. One key aspect is patient education. Pharmacists can educate patients about potential side effects, proper medication usage, and the importance of adherence to prescribed therapies. This education helps patients to recognize and report ADRs promptly, enabling timely interventions. Another critical area is medication therapy management (MTM).

Through MTM services, pharmacists can conduct comprehensive medication reviews to identify potential drug interactions, duplications, and other issues that could lead to ADRs. By optimizing medication regimens, pharmacists can reduce the likelihood of adverse events and improve patient outcomes. Pharmacovigilance is another vital component of pharmacists' role in managing ADRs. Pharmacists can actively participate in pharmacovigilance activities by reporting ADRs to relevant authorities, contributing to the detection and analysis of drug safety signals. This proactive involvement helps to enhance the overall safety profile of medications and supports the development of safer drug therapies. The review also identified several challenges that pharmacists face in managing ADRs. These challenges include limited access to complete patient medical histories, time constraints, and the need for more recognition and support for their role in pharmacovigilance. Addressing these challenges is essential to maximize the impact of pharmacists in ADR management. To improve the role of pharmacists in managing ADRs, the review proposed several strategies. One strategy is to enhance pharmacists' access to comprehensive patient health information, enabling them to make more informed decisions about medication therapy. Another strategy is to advocate for policy changes that support pharmacists' involvement in ADR management, including reimbursement for MTM services and recognition of their contributions to patient safety. Additionally, ongoing education and training for pharmacists are crucial to keep them updated on the latest developments in pharmacovigilance and ADR management. The review also emphasized the importance of leveraging technology to support pharmacists in managing ADRs. Technological tools such as electronic health records (EHRs), clinical decision support systems, and data

analytics can assist pharmacists in identifying and preventing ADRs more effectively. Integrating these technologies into pharmacy practice can enhance pharmacists' ability to monitor and manage medication safety.

4. RESULTS AND DISCUSSION

It is essential for chemists to be involved in patient education in order to reduce adverse drug reactions (ADRs). Chemists assist patients in better managing their therapies and reducing the likelihood of experiencing unwanted effects by providing information that is both clear and thorough on drugs. A variety of approaches, such as verbal counselling, written materials, and interactive instruments, are among the components that comprise effective patient education. It is common practice for chemists to provide verbal counselling in order to clarify prescription regimens, potential bad effects, and proper steps to take in the event that unwanted effects arise. This one-on-one engagement gives chemists the opportunity to address specific patient problems and provide guidance that is tailored to the individual as a whole. Patients can also benefit from having written resources, such as pamphlets and fact sheets, to serve as reference points and to reinforce the vocal instructions they have received. This can be accomplished through the utilisation of interactive tools, such as visual aids and medication management applications, which can improve patient comprehension and participation [23], [24], [25]. For patients, these tools not only help them visualise how their prescriptions operate, but they also provide reminders to take their medications and monitor any adverse effects they may have. Patients who obtain instruction guided by chemists and make use of these tools are better suited to manage their drugs and report fewer adverse drug reactions, according to research. It is also the responsibility of chemists to educate patients about the potential for adverse drug interactions. Pharmacists play an important role in preventing unpleasant reactions that may be caused by unexpected drug interactions by providing patients with information regarding the possibility of interactions with other medications, foods, or consumables.

This preventative strategy is necessary for reducing the likelihood of adverse drug reactions (ADRs) and ensuring that medication is used in a manner that is both safe and effective. The Medication Therapy Management (MTM) service is a systematic service that is provided by chemists in order to maximise the usage of medications and reduce adverse drug reactions (ADRs). The medication therapy management (MTM) process entails doing a comprehensive evaluation of a patient's whole pharmaceutical regimen, which includes prescription prescriptions, over-the-counter medications, and dietary supplements. The purpose of this endeavour is to identify and resolve issues that are associated with medication and have the potential to result in unfavourable effects or therapeutic outcomes that are less than ideal [26], [27]. There are a number of essential components that are included in the MTM process. These components include therapeutic assessments, medication reviews, and tests for drug interactions. The appropriateness, efficacy, and safety of each medicine are evaluated by chemists individually. The evaluation includes determining whether the medicine is suitable for the patient's condition, determining whether the dosage is appropriate, and determining whether there are any potential interactions with other therapies. In order to ensure that drug regimens are optimised based on the patient's overall treatment plan, chemists that provide MTM services work in collaboration with other healthcare practitioners. The effectiveness of pharmacological therapy is improved by the use of this collaborative method, which also lowers the likelihood of adverse drug reactions (ADRs). With the purpose of addressing issues regarding medicine and making any required adjustments to the patient's treatment, chemists may communicate with physicians, nurses, and other healthcare professionals [28], [29], [30].

Research demonstrates that MTM is successful in lowering the incidence of adverse drug reactions (ADRs) and increasing patient outcomes. According to research, for instance, medication therapy management (MTM) services conducted by chemists lead to a reduction in the number of hospitalisations that are caused by adverse drug reactions (ADRs) and an increase in medication adherence. Additionally, the provision of MTM services contributes to the improvement of patients' quality of life as well as the overall management of chronic illnesses. The systematic monitoring, evaluation, and reporting of adverse drug reactions (ADRs) is an essential part of pharmacovigilance, which is an essential component of

medication safety systems. It is common for chemists to be the first to recognise and report adverse drug reactions (ADRs) that patients have had, making them an essential component of pharmacovigilance protocols [31]. Documenting adverse drug reactions (ADRs) and reporting them to regulatory authorities, such as the Food and Drug Administration (FDA) or other national and international agencies, is one of the obligations that falling under the purview of pharmacovigilance for chemists. The early diagnosis of safety hazards and the formulation of actions to manage risks are both made possible through the completion of this reporting. Community pharmacies that have sophisticated pharmacovigilance systems are more likely to report greater rates of adverse drug reactions (ADRs), which in turn leads to more thorough drug safety profiles and informed regulatory actions. Pharmacists also play a part in teaching patients about the importance of recognising and reporting adverse drug reactions (ADRs) [32]. Pharmacists contribute to the collection of vital data for pharmacovigilance systems by urging patients to report any instances of adverse effects they experience. In addition to contributing to the ongoing enhancement of drug safety profiles, this proactive strategy significantly improves the overall safety and efficacy of drugs.

The reporting of adverse drug reactions (ADRs) is not the only responsibility of chemists; they must also be current on the most recent safety information and revisions. Awareness of new safety alerts, recalls, and changes to drug labelling are all included in this category. The ability to provide patients with accurate counsel and to make informed judgements on medication therapy is afforded to chemists who maintain a current knowledge of safety facts. Despite the fact that they play a crucial role in the management of adverse drug reactions (ADRs), chemists face a number of problems and impediments that can have an influence on their performance? The capacity of chemists to conduct comprehensive drug reviews and provide detailed patient education might be hindered by important difficulties such as high workloads and time restrictions [33]. Pharmacists may have difficulty dedicating sufficient time for each patient in community pharmacies that are extremely busy. This may have the potential to negatively impact the quality of their contacts with patients as well as the efficiency of their instructional efforts [34]. The failure to adequately record adverse drug reactions is still another key obstacle. The complexity of the reporting procedures and the lack of information of the reporting obligations are both factors that contribute to this problem.

Those who work in the pharmaceutical industry may have difficulty navigating adverse drug reaction (ADR) reporting systems or may not completely comprehend the significance of reporting all adverse events. An increase in awareness of the significance of pharmacovigilance, the simplification of reporting procedures, and the provision of further training for chemists are all necessary steps in addressing these obstacles. Promising solutions to these difficulties can be found in the evolution of technology. Medication management procedures can be made more efficient and streamlined by the utilisation of various technical tools, such as clinical decision support systems, electronic health records, and other technology. The use of these technologies can provide chemists with assistance in recognising probable adverse drug reactions (ADRs), monitoring medication therapy, and reporting adverse reactions in a more efficient manner. Continuous education and professional development are also essential components in the process of increasing the capacities of chemists in the management of adverse drug reactions (ADRs). Pharmacists can improve their capacity to handle adverse drug reactions (ADRs) and stay up to date with best practices by participating in training programs that focus on the most recent breakthroughs in pharmacovigilance, medications therapy management, and patient education strategies. Chemists have the ability to improve their contributions to the safety of drugs and the results for patients if they address these difficulties and make use of technological developments [35], [36].

5. CONCLUSION

Through their participation in patient education, medication therapy management (MTM), and pharmacovigilance procedures, chemists play a significant part in the reduction of adverse drug reactions (ADRs), which are also known as adverse medical responses. Through their experience and direct interactions with patients, they are able to play a pivotal role in guaranteeing the safety of medications and enhancing the effects of therapeutic interventions. The provision of extensive patient education, the

execution of complete MTM services, and the active participation in pharmacovigilance are all ways in which chemists make substantial contributions to the prevention, identification, and management of adverse drug reactions (ADRs). The issues that chemists encounter include heavy workloads and obstacles to the reporting of adverse drug reactions (ADRs), despite the fact that their function is of fundamental importance. In order to effectively address these difficulties, it is necessary to use technologies that provide support, to engage in continuous education and training, and to promote collaboration across disciplines. Technological innovations, including as electronic health records and clinical decision support systems, provide the potential to expedite operations and improve efficiency. Additionally, continual professional development ensures that chemists are always up-to-date with the most effective methods. It is necessary for chemists to play a role in lowering adverse drug reactions (ADRs) in order to protect patient health and maximise the utilisation of medications. Through the overcoming of obstacles and the use of technology advancements, chemists have the ability to improve their efficiency in the treatment of adverse drug reactions (ADRs), hence contributing to enhanced patient safety and therapeutic outcomes. As the healthcare environment continues to change, their increased duties will continue to be essential, which highlights the necessity of providing them with ongoing assistance and acknowledging the contributions they have made to the issue of medication safety.

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions Statement

Name of Author	C	M	So	Va	Fo	I	R	D	O	E	Vi	Su	P	Fu
Fahad Nabi	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓	✓
Mohd Altaf Dar	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Abrar Bashir Malik	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓	✓

C : **C**onceptualization
M : **M**ethodology
So : **So**ftware
Va : **Va**lidation
Fo : **Fo**rmal analysis
I : **I**nvestigation
R : **R**esources
D : **D**ata Curation
O : Writing - **O**riginal Draft
E : Writing - Review & **E**diting
Vi : **Vi**sualization
Su : **Su**pervision
P : **P**roject administration
Fu : **Fu**nding acquisition

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

Not Applicable.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

[1] M. Zehravi and M. Maqbool, "Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health," vol. 34, pp. 1-9, Jul. 2021. doi.org/10.1515/ijamh-2021-0073

[2] R. J. Lihite et al., "A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine," vol. 53, pp. 151-156, Jul. 2017. doi.org/10.1016/j.ajme.2016.05.007

[3] M. Zehravi and M. Maqbool, "Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview," International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 339-345, Jun. 2021. doi.org/10.1515/ijamh-2021-0058

[4] M. Maqbool, F. Bekele, and G. Fekadu, "Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy," pp. 15-24, Jan. 2022. doi.org/10.2147/BCTT.S348060

[5] S. Rasool and M. Maqbool, "An overview about Hedychium spicatum: a review," vol. 9, pp. 476-480, Feb. 2019. doi.org/10.22270/jddt.v9i1-s.2429

[6] M. Zehravi and M. Maqbool, "Depression and anxiety in women with polycystic ovarian syndrome: a literature survey," International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 367-373, Aug. 2021. doi.org/10.1515/ijamh-2021-0092

[7] M. Maqbool, I. Gani, and M. A. Dar, "Anti-diabetic effects of some medicinal plants in experimental animals: a review," Asian Journal of Pharmaceutical Research and Development, vol. 7, no. 1, pp. 66-69, Feb. 2019. doi.org/10.22270/ajprd.v7i1.469

[8] M. Zehravi and M. Maqbool, "Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health," vol. 33, pp. 333-337, Apr. 2021. doi.org/10.1515/ijamh-2021-0031

[9] M. Mohd, M. Maqbool, M. A. Dar, and I. Mushtaq, "Polycystic ovary syndrome, a modern epidemic: an overview," Journal of Drug Delivery and Therapeutics, vol. 9, no. 3, pp. 641-644, May 2019. doi.org/10.22270/jddt.v9i3.2661

[10] M. Maqbool et al., "An up to date on clinical prospects and management of osteoarthritis," Annals of Medicine and Surgery, vol. 72, Dec. 2021. doi.org/10.1016/j.amsu.2021.103077

[11] A. Majeed, R. Bashir, S. Farooq, and M. Maqbool, "Preparation, characterization and applications of nanoemulsions: An insight," Journal of Drug Delivery and Therapeutics, vol. 9, no. 2, pp. 520-527, Mar. 2019. doi.org/10.22270/jddt.v9i2.2410

[12] M. Zehravi and M. Maqbool, "Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health," vol. 3, pp. 60-65, May 2022. doi.org/10.1515/openhe-2022-0008

[13] R. Maqbool, M. Maqbool, and M. Zehravi, "Menstrual distress in females of reproductive age: a literature review. International journal of adolescent medicine and health," vol. 34, pp. 11-17, Jul. 2021. doi.org/10.1515/ijamh-2021-0081

[14] I. Ara, M. Maqbool, G. Fekadu, T. A. Hajam, and M. A. Dar, "Pharmaceutical significance of Nigella sativa L., a wonder herb," Journal of Applied Pharmaceutical Sciences and Research, vol. 3, no. 4, pp. 4-13, 2020. doi.org/10.31069/japsr.v3i4.2

[15] M. Maqbool, N. Nasir, and S. Mustafa, "Polycystic in ovarian syndrome and its various treatment strategies," INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 5, no. 9, pp. 8470-8478, Sep. 2018.

[16] M. Maqbool, M. Zehravi, and R. Maqbool, "Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital," India. CELLMED, vol. 11, no. 2, pp. 8-9, 2021.

[17] I. Ara, M. Maqbool, B. Bukhari, and A. N. Hajam, "Present status, standardization and safety issues with herbal drugs," International Journal of Research in Pharmaceutical Sciences and Technology, vol. 1, no. 3, pp. 95-101, May 2020. doi.org/10.33974/ijrpst.v1i3.169

[18] I. Ara, M. Maqbool, and I. Gani, "Reproductive Health of Women: implications and attributes," International Journal of Current Research in Physiology and Pharmacology, pp. 8-18, Nov. 2022.

[19] M. Zehravi, R. Maqbool, and M. Maqbool, "To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar," Journal of Pharmaceutical Research International, vol. 33, no. 31A, pp. 135-140, Jun. 2021. doi.org/10.9734/jpri/2021/v33i31A31673

[20] M. Maqbool, S. Javed, and A. A. Bajwa, "Assessment OF pain management IN postoperative cases using different scales and questionnaires," INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 6, no. 1, pp. 983-987, Jan. 2019.

[21] I. Ara, M. Maqbool, and M. Zehravi, "Psychic consequences of infertility on couples: A short commentary. Open Health," vol. 3, pp. 114-119, Jan. 2022. doi.org/10.1515/openhe-2022-0022

[22] R. Bashir, M. Maqbool, and A. I. Zehravi, "An Insight into Novel Drug Delivery System," In Situ Gels. CELLMED, vol. 11, no. 1, pp. 6-7, 2021.

[23] M. Zehravi and M. Maqbool, "Teenage menstrual dysfunction: an overview," International Journal of Adolescent Medicine and Health, vol. 35, no. 1, pp. 15-19, Sep. 2022. doi.org/10.1515/ijamh-2022-0018

[24] I. Ara, M. Zehravi, M. Maqbool, and I. Gani, "A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries," Journal of Pharmaceutical Research & Reports, no. 3, 2022.

[25] M. Maqbool, W. Shabbir, and S. Aamir, "Adverse events of blood transfusion and blood safety in clinical practice," Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8254-8259, Aug. 2018.

[26] M. Maqbool, A. Naeem, and S. Aamer, "Diabetes mellitus and its various management strategies in practice," Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, Aug. 2018.

[27] M. Maqbool, S. Tariq, and S. Amjad, "Prescribing practices in pediatrics and drug utilization studies promoting pediatric health," Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.

[28] M. Maqbool, U. Ikram, and A. Anwar, "Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders," Indo American Journal of Pharmaceutical Sciences, vol. 5, no. 8, pp. 8060-8065, Aug. 2018.

[29] R. Maqbool, M. Maqbool, and M. Zehravi, "Acute neurological conditions during pregnancy and their management: a review," International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084

[30] M. Zehravi and M. Maqbool, "An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India," The Indian Journal of Nutrition and Dietetics, pp. 408-418, Jul. 2021. doi.org/10.21048/IJND.2021.58.3.27285

[31] M. Maqbool and M. Zehravi, "Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation," vol. 1, Dec. 2021. doi.org/10.5812/ipmn.117170

[32] M. Maqbool and A. I. Gani, "The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age," International Journal of Current Research in Physiology and Pharmacology, pp. 19-31, Nov. 2022.

[33] M. Maqbool and I. Gani, "Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review," Journal of Pharmacy Practice and Community Medicine, vol. 4, no. 4, 2018. doi.org/10.5530/jppcm.2018.4.46

[34] Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23; 33(6):357-66. doi.org/10.1515/ijamh-2021-0084

[35] Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1; 5(8):8070-6.

[36] Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1; 5(8):8163-+.

How to Cite: Fahad Nabi, Mohd Altaf Dar, Abrar Bashir Malik. (2023). Guardians of safety: the crucial role of pharmacists in reducing adverse drug reactions. Journal of Community Pharmacy Practice (JCPP), 3(2), 33-42. https://doi.org/10.55529/jcpp.34.36.46

BIOGRAPHIES OF AUTHORS

	**Fahad Nabi,** works as a researcher with the Department of Pharmacology at CT Institute of Pharmaceutical Sciences, PTU in Jalandhar, Punjab, India. His focus is on pharmacology. He also studies safe use of medicines and pharmacovigilance. Along with that, he looks at adverse drug reactions. He is interested in community pharmacy. He also pays attention to patient care. Fahad has written research and review papers. Some of his work covers medication counselling. Other topics include how pharmacists and doctors communicate. He has also worked on stopping adverse drug events.
	**Mohd Altaf Dar,** works as a researcher in the Department of Pharmacology at CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India. His main academic focus is on pharmacology. He is also interested in pharmacovigilance and medication safety. Adverse drug reactions are another key area for him. He has looked into community pharmacy as well. He follows topics linked to chronic diseases too. Healthcare management is part of his work. In his publications, he has covered medication counselling. He has also written on how to help prevent adverse drug events. Email: daraltaf490@gmail.com
	**Abrar Bashir Malik,** works as a researcher in the Department of Pharmacology at the CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India. He focuses on pharmacology and also looks at pharmacovigilance and medication safety. His work covers adverse drug reactions and how they affect patient care. He is interested in cardiovascular diseases too. In addition, he has written research and review articles. His topics include medication counselling, ways to stop adverse drug events, coronary artery disease, and patient safety.